TLSI
TriSalus Life Sciences, Inc. (TLSI) Risks & Opportunities Analysis (2026)
Risks
Negative interest coverage and elevated debt-to-equity increase refinancing sensitivity, leaving TLSI less resilient than peers with positive earnings coverage and cleaner balance sheets.
A 77-day cash conversion cycle, driven by 240 days of inventory, ties up working capital and can pressure liquidity versus faster-turning direct peers.
Inventory intensity remains a downside if demand softens, because slower sell-through can force discounting and margin compression relative to leaner competitors.
High payables offset some working-capital strain, but the stretched supplier financing profile can narrow flexibility versus peers with shorter operating cycles.
Opportunities
A current ratio above 5.0 provides substantial near-term liquidity, giving TLSI more buffer than many peers to absorb demand volatility or delayed collections.
Net debt to EBITDA below 1.0 suggests leverage is manageable versus more indebted peers, which can support capacity to fund growth or working-capital needs.
Strong quick liquidity relative to peers reduces near-term funding risk, improving positioning if customers or distributors extend payment terms.
If inventory normalizes, the large working-capital base could release cash faster than peers with tighter liquidity, improving financial flexibility.
Overall Score
TLSI’s forward positioning is constrained by weak earnings coverage and heavy inventory, but strong liquidity and moderate leverage provide meaningful offset versus peers.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on TriSalus Life Sciences, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

